Survival from non-Hodgkin lymphoma in England and Wales
Author Information
Author(s): Johnson P W M
Primary Institution: NCRI Lymphoma Clinical Studies Group, CR UK Clinical Centre, Southampton General Hospital
Conclusion
The rising survival figures for non-Hodgkin lymphoma are encouraging and likely to continue improving due to advancements in treatment.
Supporting Evidence
- The introduction of monoclonal antibodies has significantly improved treatment outcomes.
- High-dose therapy has shown survival benefits in certain lymphoma types.
- Supportive care improvements have contributed to better survival rates.
Takeaway
This study looks at how people with non-Hodgkin lymphoma are living longer now than before, thanks to better treatments.
Potential Biases
There may be biases related to the exclusion of patients unfit for intensive therapy in clinical trials.
Limitations
The study's findings may be underrepresented due to changes in patient demographics and case mix over time.
Participant Demographics
The study discusses an increase in older patients and those with immunodeficiency-related lymphomas.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website